ImQuest to file IND of anti-HIV drug

ImQuest Pharmaceuticals Inc. expects to submit an IND in the United States to initiate Phase 1 human clinical trials with IQP·0410, a highly potent member of the pyrimidinedione series in the third quarter of 2008, according to Samjin Pharm.

ImQuest licensed entire series of anti-HIV therapeutic compounds from Samjin in 2005.

ImQuest has obtained funding from the National Institutes of He...